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Background: Preimplantation genetic diagnosis (PGD) enables profiling of embryos for genetic disorders prior to
implantation. The majority of PGD testing is restricted in the scope of variants assayed or by the availability of
extended family members. While recent advances in single cell sequencing show promise, they remain limited by
bias in DNA amplification and the rapid turnaround time (<36 h) required for fresh embryo transfer. Here, we
describe and validate a method for inferring the inherited whole genome sequence of an embryo for
preimplantation genetic diagnosis (PGD).
Methods: We combine haplotype-resolved, parental genome sequencing with rapid embryo genotyping to predict
the whole genome sequence of a day-5 human embryo in a couple at risk of transmitting alpha-thalassemia.
Results: Inheritance was predicted at approximately 3 million paternally and/or maternally heterozygous sites with
greater than 99% accuracy. Furthermore, we successfully phase and predict the transmission of an HBA1/HBA2
deletion from each parent.
Conclusions: Our results suggest that preimplantation whole genome prediction may facilitate the comprehensive
diagnosis of diseases with a known genetic basis in embryos.Background
Preimplantation genetic diagnosis (PGD) enables profil-
ing of embryos for genetic disorders prior to implant-
ation. Multiple embryos created by in vitro fertilization
(IVF) are biopsied and screened for aneuploidy and/or
single-gene mutations, followed by selective implantation
of euploid embryos lacking the targeted disease alleles. A
variety of approaches have been developed using different
DNA sources (polar body, blastomere, trophectoderm), and
different molecular techniques (for example, PCR, FISH,
SNP array, or arrayCGH) [1-6]. Although it is in widespread
clinical use, current practices for PGD are generally directed
at specific loci and/or at chromosomal aberrations [1,7].
In principle, it should be possible to determine the entire
genome sequence directly from an embryo, for instance
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unless otherwise stated.disorders or complex, multifactorial phenotypes. However,
progress towards this goal is challenged by several prac-
tical considerations. First, stochastic biases during the
amplification of minute quantities of genomic DNA ob-
tained from embryo biopsies (1 to 10 cells each) both limit
and obscure the ascertainment of inherited alleles, while also
introducing artifactual mutations [8-10]. Second, single-cell
amplification and whole genome sequencing workflows still
exceed the 1- to 5-day turnaround time necessary for fresh
embryo transfer. Although there have been recent important
advances with respect to both low-input amplification pro-
tocols and the speed of DNA sequencing [11-14], existing
methods are either unable to predict the whole genome
sequences of embryos or will necessitate extensive changes
in the handling/preparation of embryo biopsies to do so.
Here we show that the combination of rapid embryo
genotyping and molecular phasing of parental genomes
can be used to predict the whole genome sequence of an
embryo within a timeframe suitable for fresh transfer (or
alternatively with frozen transfer). This work builds on
recently developed methods to experimentally determine
an individual’s haplotypes on a genome-wide scaleThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kumar et al. Genome Medicine  (2015) 7:35 Page 2 of 8[14-18]. We begin by using genotypes from parents and
sibling embryos to accurately predict a sparse subset of ge-
notypes from single or few-cell embryo biopsies despite sub-
stantial allele dropout observed in single-cell amplification
[19]. We then combine this information with haplotype-
resolved genome sequencing of both parents to predict the
inherited genome sequence of the embryo.
Methods
DNA isolation, whole-genome shotgun library preparation,
sequencing, and variant calling
DNA from subjects was obtained after written informed
consent. This study was approved by the E&I West Coast
Board Institutional Review Board and conducted in ac-
cordance with the Declaration of Helsinki. Genomic DNA
was extracted from whole blood or saliva samples, as avail-
able. Purified DNA was fragmented by sonication with the
Covaris S2 instrument. Shotgun sequencing libraries were
prepared by either the KAPA library preparation kit (Kapa
Biosystems) or ThruPLEX-FD (Rubicon Genomics) fol-
lowing manufacturer’s instructions. All libraries were
sequenced on HiSeq 2000 instruments (Illumina) using
paired-end 100-bp reads. Reads were mapped to the hu-
man reference genome sequence (hg19) with bwa v0.7.1
[20]. After removal of PCR duplicate pairs using the Picard
toolkit, local realignment around indels, variant dis-
covery, and quality score recalibration were performed
with the Genome Analysis Toolkit (GATK) [21] using
standard procedures with an additional filter (HRun <5)
to remove potentially spurious variants near mononucleo-
tide repeats [21].
Dilution pool construction, sequencing, and haplotype
phasing
Haplotype-resolved genome sequencing was performed for
each parent using a modified Long Fragment Read proto-
col [11] involving limiting dilution of DNA into 96-well
plates followed by amplification, library preparation, se-
quencing, and alignment (Additional file 1: Note S1). Frag-
ment boundaries were determined as previously described
[16] and basecalls were made at heterozygous sites pre-
viously determined by whole genome sequencing. Over-
lapping fragments were assembled into haplotype
blocks using the RefHap haplotype assembly package [22]
(Additional file 1: Note S2). These ‘molecular haplotypes’
were subsequently expanded by local statistical phas-
ing using haplotypes from the 1000 Genomes project
(Additional file 1: Note S3).
Copy number estimates from whole genome sequencing
Read depths from bwa alignments were aggregated in
100-bp windows and divided by the mean autosomal
read depth to correct for differing amounts of coverage
between samples. Each library was individually correctedusing a smoothed linear model of read depths to G + C
composition at each window, as previously described in
Sudmant et al. [23].
Embryo genotyping and ‘Parental Support’ analysis
Genotyping was performed on trophectoderm biopsies
(day-5, n = 10). Embryo biopsies were subjected to DNA
extraction, amplification and genotyping with parents
and grandparents using a rapid microarray protocol as
previously described in Johnson et al. [6] with the Illu-
mina CytoSNP-12 chip used across all samples. Sibling
embryo and parent SNP array measurements were com-
bined to improve accuracy of embryo genotypes in the
‘Parental Support’ (PS) method [24] (Additional file 1:
Figures S1 and S2). First, a statistical model was employed
to determine the Maximum Likelihood Estimate (MLE)
phase of heterozygous SNVs in each parent by combining
recombination frequencies from the HapMap database
[25] with SNP array measurements from parents and SNP
array measurements from sibling embryos (Additional
file 1: Note S4). Second, PS embryo genotypes were de-
termined using an HMM that finds the most likely paren-
tal haplotype transmitted to each embryo given SNP array
measurements from the embryo and MLE phase for each
parent (Additional file 1: Note S5).
Whole genome prediction of inherited variants
The whole genome sequence of the embryo was pre-
dicted by combining PS embryo genotypes with parental
haplotype blocks (Additional file 1: Figures S3, S4, and S5).
For each haplotype block, which can be assumed to have
two haplotypes A or B, transmission was determined based
on the intersection of sites contained in each block and
sites called by PS embryo genotypes. The haplotype block
(A or B) with the highest score was considered to be
transmitted. In the event that a block appeared to be par-
tially transmitted, the block was split conservatively with
new boundaries defined by the location of the nearest two
embryo genotypes (Additional file 1: Figure S5). Transmis-
sion of each of these sub-blocks was determined inde-
pendently. This process was continued across the entire
genome for both the mother and father (Additional file 1:
Figure S3). To predict transmission of heterozygous dele-
tions, we manually selected high-quality haplotype blocks
from dilution pool sequencing that overlapped the dele-
tion of interest and used other heterozygous SNVs within
the haplotype block to determine whether the deletion
was transmitted to the embryo.
Incorporating grandparental information into analysis
Parental haplotypes were obtained using GATK Phase-
ByTransmission with variants from shotgun sequencing
of parents and grandparents used as inputs. Phased ge-
notypes were subsequently incorporated into parental
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file 1: Note S6). The embryo genome was predicted as pre-
viously described both with and without grandparental ge-
notypes and the union of calls was used to determine the
increase in prediction coverage with grandparents. Add-
itionally, the embryo genome was predicted with just the
grandparental information as well as with only the grand-
parental genotypes plus the population phased estimates
as described in Additional file 1: Note S3. Parental variants
were annotated using Variant Effect Predictor [26].
Results
Materials used in this study were retrospectively obtained
from a couple at risk of transmitting alpha-thalassemia
that previously underwent a successful round of IVF with
preimplantation genetic diagnosis (Additional file 1: Table S1).
We obtained trophectoderm biopsies from a total of 10
embryos (day 5) and genotyped each across a panel of
300,000 common SNPs using an expedited, 24-h microarray
protocol [6]. Additionally, we genotyped each parent and all
four grandparents across the same panel (Figure 1).
To determine accurate embryo genotypes, we developed
an approach we term ‘Parental Support’, which is an in-
formatics technique that uses relatives’ samples including
any combination of parents, siblings, and sperm to inferFigure 1 Experimental approach. (a) Parental genomes were haplotype-r
population-based phasing. Embryo biopsies were genotyped using a ra
from parents and sibling embryos to infer a sparse set of ‘Parental Sup
sites from PS embryo genotyping were combined with haplotype-resolved p
the embryo.genotypes [24,27]. In this case, we combined SNP array
measurements from parents and sibling embryos with re-
combination frequencies [27] in a statistical model to de-
termine the Maximum Likelihood Estimate (MLE) of
phase for heterozygous SNVs in each parent, transmission
of parental haplotypes to each embryo, and the location of
possible sites of meiotic recombination (Additional file 1:
Figures S1 and S2) [24,25,28,29]. This approach results
in accurate inference of transmission to the embryo for
approximately 120,000 parentally heterozygous sites, here-
after referred to as ‘Parental Support’ (PS) embryo geno-
types (Figure 2a and Table 1).
We next sought to incorporate information from
haplotype-resolved genome sequencing of both parents.
To discover transmissible variants, we first performed
shotgun sequencing of the mother and father to 34× and
30× median fold coverage, respectively (Additional file 1:
Figure S3a and Table S2). Next, by sequencing haploid
subsets of genomic DNA obtained via in vitro dilution
pool amplification, we directly phased 94.2% of 1.94 mil-
lion heterozygous SNVs in the mother and 92.4% of 1.89
million heterozygous SNVs in the father into long haplo-
type blocks [11,14-16,22,30]. To further improve paren-
tal haplotypes, we incorporated population-based phase
using BEAGLE [31] and sequencing data from the 1000esolved using a combination of direct molecular methods and
pid SNP-array protocol and processed using information derived
port’ (PS) genotypes. (b) Prediction of the embryo genome. Informative
arental genome sequences to predict the whole genome sequence of
Figure 2 Results of embryo predictions. (a) Predicted transmission of parental haplotypes to the embryo after rapid array-based genotyping with
‘Parental Support’. A hidden Markov model incorporating parental phase and SNP array measurements of an embryo was used to obtain the
probability of each parental haplotype being transmitted into each embryo. These states and state probabilities were used to determine which
parental haplotypes composed the embryo genome and to define the location of meiotic recombination events. The example shown here is
colored according to grandparental haplotype after incorporating SNP array measurements from grandparents within predictions. M: Maternal;
P: Paternal. (b) Phasing of HBA1/HBA2 deletion in the embryo’s father via dilution pool sequencing. The deletion was identified using whole
genome sequencing (WGS). The HBA1/HBA2 containing haplotype was determined by identifying multiple dilution pools that overlapped the
deleted region (in blue). Transmission of this haplotype was predicted by comparing informative PS embryo genotyping sites (blue letters) with
corresponding sites within parental haplotypes.
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Table 1 Summary of haplotype sources and the number of variants phased/predicted
Technique Mother Father Mother
(% of all het variants)
Father
(% of all het variants)
‘Parental Support’ embryo genotypes Phased 75,869 73,622 3.9% 3.9%
Phased and predicted 73,003 71,362 3.8% 3.8%
(+) Phasing by dilution pool sequencing Phased 1,829,314 1,751,004 94.2% 92.4%
Phased and predicted 1,672,932 1,589,836 86.2% 83.9%
(+) Phasing by population reference panel Phased 1,840,200 1,895,730 97.1% 97.6%
Phased and predicted 1,732,641 1,775,614 91.4% 91.5%
(+) 10× sequence from grandparents Phased 1,922,421 1,875,363 99.0% 98.9%
Phased and predicted 1,880,092 1,847,297 96.8% 97.5%
Sites determined by comparison with Illumina trio sequencing (including the offspring) to have poor genotype quality scores or genotypes that violated
Mendelian inheritance were discarded for the purpose of evaluating accuracy.
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tional phasing in Selvaraj et al. [18]. This approach in-
creased the proportion of SNVs phased to 97.1% in the
mother and 97.6% in the father.
We then combined PS embryo genotypes with paren-
tal haplotypes to predict inherited variation, genome-
wide, in the embryo (Additional file 1: Figure S3b). We
inferred transmission of parental haplotype blocks based
on the intersection of the sites contained in these blocks
and sites called by PS embryo genotypes. Using this ap-
proach, transmission of 28,402 blocks including 83.9% of
paternal SNVs and 25,733 blocks including 86.2% of ma-
ternal SNVs were successfully predicted. The addition of
population-based phasing estimates resulted in a 4% to
10% increase in the number of SNVs predicted, such that
after this step, transmission of 18,850 blocks representing
91.5% of paternal SNVs and 17,233 blocks representing
91.4% of maternal SNVs were predicted.
A small minority of haplotype blocks appeared to be
only partially transmitted (419 blocks; 2.2%). While some
of these may correspond to meiotic recombination events
within parental gametes, most are likely switch errorsTable 2 Prediction accuracy for embryo genotypes
Individual Site Other pa








Transmission predictions for this analysis made use of PS embryo genotypes as wel
but did not make use of grandparental genotypes. Accuracy defined as the percent
determined by comparison with Illumina trio sequencing (including the offspring) t
inheritance were discarded for the purpose of evaluating accuracy. A total of 312,69
categories above with ‘NA’ in accuracy column).
NA: not applicable.in the parental haplotypes that resulted from unresolved
collisions within the process of dilution pool sequencing
(Additional file 1: Figure S4). We corrected for these
cases by splitting each affected block at the site of the
switch and inferring transmission of the resulting blocks
individually.
We assessed the accuracy of our approach by compar-
ing these predictions against the embryo’s true genotypes,
as determined by whole genome sequencing of saliva from
the resulting newborn. We excluded sites with poor geno-
type quality scores in any individual within the trio, as well
as sites that violated Mendelian inheritance, leaving a total
of 3.19 million sites heterozygous within one or both par-
ents (number of heterozygous sites: 1,297,649 maternal-
only, 1,251,550 paternal-only; 643,886 both) (Table 1). A
total of 312,698 (9.8%) sites were unable to be called in
the embryo because transmission could not be predicted
from one or both parents. Of the remaining 2.88 million
sites (90.2%), we successfully predicted the embryo geno-
type with 99.5% accuracy (Tables 1 and 2). If we restrict
our predictions to sites where only one parent is heterozy-
gous, 90.9% of paternal-only heterozygous sites and 91.0%rental genotype Number of sites Accuracy
ous 1,138,851 99.5%
ous, predicted 561,745 99.5%
ous, unpredicted 32,045 NA
112,699 NA
ous 1,179,791 99.5%
ous, unpredicted 34,078 NA
ous 117,858 NA
ous, unpredicted 16,018 NA
l as molecular haplotyping and population-phasing of the parental genomes,
age of transmitted alleles correctly predicted, out of all predicted sites. Sites
o have poor genotype quality scores or genotypes that violated Mendelian
8 sites were omitted due to unsuccessful phasing in either parent (sum of
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99.5% accuracy (Additional file 1: Table S3).
Among erroneously predicted sites, 57% (n = 8,421)
occurred in ‘clusters’ of two or more adjacent sites, sug-
gesting that most inaccuracies result from improper paren-
tal phasing or incorrect prediction of meiotic breakpoints.
Sites for which we were unable to make predictions failed
at different stages of analysis (Additional file 1: Figure S5)
with the majority (72%, n = 227,675) phased into haplotype
blocks but not predicted with respect to transmission due
to sparse measurement in the embryo. Prediction of these
sites could be improved either by increasing the size of
parental haplotype blocks or by increasing the number of
measurements made on the embryo (for example, using
denser SNP arrays). To estimate the potential for improve-
ment by using a higher density SNP array, we simulated
the discovery of additional embryo genotypes and repeated
our predictions. We estimated that increasing the number
of PS embryo genotypes consistent with the use of the
Illumina 1 M array would boost coverage from 90.2% to
approximately 94% (Additional file 1: Figure S6).
To investigate how predictions would improve with the
availability of grandparental genotypes, we sequenced the
genomes of the embryo’s four grandparents to 10× depth.
We phased each parent’s genome using variants called
from shotgun sequencing of maternal and paternal grand-
parents and combined the resulting haplotypes with the
blocks determined by in vitro dilution pool phasing. The
inclusion of grandparental genotypes increased the num-
ber of positions for which predictions could be made in the
embryo to 3.10 million sites (97.2%) with a slight decrease
in accuracy from 99.5% to 99.3% (possibly due to errors in-
troduced when phasing using low-coverage grandparental
genomes). If we restrict our predictions to sites where only
one parent is heterozygous, 97.6% of paternal-only hetero-
zygous sites could be predicted with 99.4% accuracy, while
96.8% of maternal-only heterozygous sites could be pre-
dicted with 99.3% accuracy (Additional file 1: Table S3).
Both parents were carriers of a 40-kb deletion at the
alpha hemoglobin locus (HBA1/HBA2), and underwent
PGD testing to select for embryos carrying only non-
deletion alleles. The clinical test was originally performed
by phasing the deletion to a haplotype using DNA from
grandparents and subsequently inferring which parental
haplotype was transmitted to the child. In our approach,
we set out to predict transmission in the absence of grand-
parental haplotypes, both at the HBA locus and genome-
wide. We first phased the deletion in each parent with
neighboring SNVs [23]. We manually selected haplotype
blocks overlapping the deletion and identified neighboring
heterozygous SNVs in these blocks that were also geno-
typed within the embryo (Figure 2b). Both parents trans-
mitted SNVs that were linked to intact HBA1 and HBA2
haplotypes, thus we predicted that the embryo did notinherit the HBA1/HBA2 deletion from either parent. Our
results were consistent with the clinical PGD prediction
and with the genome sequence of the resulting newborn
(Additional file 1: Table S4).
Discussion
We present an approach to predict the inherited whole
genome sequence of a human embryo through a com-
bination of rapid genotyping of multiple embryo biopsies
and haplotype-resolved parental genome sequencing. The
types and quantities of materials used are consistent with
those routinely collected in a clinical PGD setting. Import-
antly, all embryo genotyping data used in this study
were obtained using a rapid genotyping protocol that is
already in use for chromosomal screening (Additional
file 1: Figure S7) and haplotype-resolved parental gen-
ome sequences can readily be determined in advance of
PGD [6].
From a technical perspective, the prediction of an em-
bryo genome as described here differs in several key
ways from the prediction of a fetal genome through se-
quencing of maternal plasma [33,34]. Specifically, fetal
genome prediction involved millions of noisy but poten-
tially informative measurements that are the result of se-
quencing a mixture of fetal and maternal cell-free DNA
fragments. In contrast, the approach described here uses
products of whole genome amplification that have been
genotyped using SNP arrays and thus results in fewer in-
formative measurements - about 50,000 to 75,000 inform-
ative SNVs within each embryo. Additionally, single gene
PGD involves biopsy of multiple embryos per cycle (aver-
age n = 5.9 according to a recent study) and our approach
uses these sibling embryos to phase parental genomes
[35]. Fresh embryo transfer requires a rapid (24-h) turn-
around for any genomic assay although a trend towards
frozen embryo transfer could alleviate that restriction. Fi-
nally, and perhaps most importantly, the sparseness of
embryo biopsy genotype estimates is such that it is critical
that parental haplotype phase estimates are highly accur-
ate (that is, with few switch errors).
The ability to infer inherited variation genome-wide
with high accuracy and completeness could have pro-
found implications for the future of PGD. A growing area
in PGD relies on testing for the presence of single gene
Mendelian disorders within embryos. While flexible methods
such as karyomapping are gaining in use, these require
related samples such as grandparents or other family
members/specimens to phase variants at the outset
[19,36,37]. The inferred genome sequence of an embryo
could potentially be used to simultaneously test for all
inherited Mendelian diseases for which the genetic basis is
well understood, as well as digenic and multigenic disor-
ders like Bardet-Biedl syndrome and Hirschsprung’s dis-
ease. Additionally, although many challenges remain, we
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from genetic information [38-40]. However, as large num-
bers of variants contribute to complex disease, genome-
wide analysis is likely to be critical for risk prediction. We
note that because haplotypes can be determined experi-
mentally, our approach does not require grandparental
DNA, enabling broader application of this technology, al-
though the comprehensiveness of predictions clearly in-
creased when it is available.
There remain several major limitations and key ave-
nues for improvement. First, somatic mosaicism within an
embryo (primarily with respect to karyotype) can con-
found genome predictions, and thus the genome of an
embryo biopsy may not fully represent the genome of the
resulting fetus. Second, our approach does not detect de
novo copy number alterations or de novo point mutations
that arise within the parental gametes. Large de novo copy
number alterations can potentially be identified from SNP
array data, although this was not attempted in this study.
While this work was in review, Peters et al. published
a related method that uses dilution pool sequencing of
cells from trophectoderm biopsies to determine more
than 80% of de novo mutations in an embryo with high ac-
curacy [41]. The approach is very compelling, but the time
and labor required after embryo biopsy necessitates
embryo freezing. By contrast, our approach can work
with both fresh and frozen embryos and does not neces-
sarily require any changes to a clinically available PGD
procedure.
Another limitation is that although we were able to
predict approximately 3 million sites in the embryo with
high accuracy, we were unable to make predictions at
over 300,000 sites. These sites were missed primarily due
to incomplete parental haplotypes but also the relative
sparseness of embryo genotyping. As technologies for
haplotype-resolved genome sequencing continue to im-
prove, for example, [17], and as denser embryo genotyping
is performed, we anticipate that a higher proportion of the
embryo genome will be predictable by this general strat-
egy. The cost of this method remains prohibitive for rou-
tine clinical use, especially when compared with methods
that rely on more conventional molecular techniques (for
example, PCR, FISH, arrayCGH), largely due to the cost
of whole genome sequencing and haplotyping each parent
(Additional file 1: Table S5). Finally, multiple clinical stud-
ies with many more samples are needed to fully validate
this method for whole genome prediction.
Nonetheless, this proof-of-concept was completed using
tools and methods that are readily available. Genotyping
arrays are in routine use for chromosome screening of
embryos following IVF. Similarly, technologies for per-
forming haplotype-resolved genome sequencing are prolif-
erating and maturing, with steady improvements in the
length and accuracy of the resulting haplotype blocks.Modest improvements in either protocol will likely in-
crease the accuracy and coverage of our predictions, and
the costs of whole genome sequencing are more generally
expected to continue to fall.
Conclusions
In this study, we introduce a method for predicting the
genome of an embryo by combining haplotype-resolved
genome sequencing of parents with rapid embryo geno-
typing. We use this approach to predict the transmission
of approximately 3 million paternally and/or maternally
heterozygous sites with greater than 99% accuracy. We
also predicted the transmission of a 40 kb HBA1/HBA2
deletion in the embryo. This approach extends preim-
plantation screening to potentially include all Mendelian
disorders as well as complex diseases with a defined gen-
etic basis. Importantly, our approach does not require
substantial changes to the current practice of preimplanta-
tion genetic diagnosis. As sequencing methods continue
to improve, we anticipate that this approach could be a
valuable addition to preimplantation testing.
Additional file
Additional file 1: Supplementary materials. This file describes a
detailed description of the bioinformatics methods and experimental
work used in this study.
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